ArticleACS omega2023
Design and Synthesis of 2-(4-Bromophenyl)Quinoline-4-Carbohydrazide Derivatives
Article in ACS omega, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 27 citations in OpenAlex.
- Quinoline Heterocyclic Clubbed Hydrazone Derivatives as Potential Inhibitors of MutantCurrent medicinal chemistry · 2026Article
- Microwave-assisted synthesis andRSC advances · 2025Article
- Therapeutic Potental of Quinolin-2Mini reviews in medicinal chemistry · 2025Review
- Design and synthesis of novel 2-(2-(4-bromophenyl)quinolin-4-yl)-1,3,4-oxadiazole derivatives as anticancer and antimicrobial candidates:RSC advances · 2024Article
- Design, synthesis, and antiproliferative screening of new quinoline derivatives bearing aRSC advances · 2024Article
- Article
- Exploring the antitumor potential of novel quinoline derivativesRSC advances · 2024Article
- Synthesis, biofilm formation inhibitory, and inflammation inhibitory activities of new coumarin derivatives.Scientific reports · 2024Article
- Design, synthesis and antiproliferative screening of newly synthesized coumarin-acrylamide hybrids as potential cytotoxic and apoptosis inducing agents.RSC advances · 2023Article
- Novel Acrylate-Based Derivatives: Design, Synthesis, Antiproliferative Screening, and Docking Study as Potential Combretastatin Analogues.ACS omega · 2023Article
- Novel peptide inhibitors targeting CD40 and CD40L interaction: A potential for atherosclerosis therapy.Current research in structural biology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microbial DNA gyrase is regarded as an outstanding microbial target. Hence, 15 new quinoline derivatives (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.